MedTrace Logo

A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir

NCT02262715 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2014-11-04

No results posted yet for this study

Summary

The purpose of this study is to investigate the drug-drug interaction between VX-787 and oseltamivir, when co-administered at steady-state in healthy participants. In addition the safety, tolerability and pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) of VX-787 will be assessed.

Conditions

  • Healthy

Interventions

DRUG

VX-787

Participants will receive VX-787, 600 mg either two times a day or once a day in either of the Part.

DRUG

Oseltamivir

Participants will receive Oseltamivir 75 mg either two times a day or once a day in either of the Part.

OTHER

Placebo

Participants will receive placebo matching to VX-787 either two times a day or or once a day.

Sponsors & Collaborators

  • Janssen Infectious Diseases BVBA

    lead INDUSTRY

Principal Investigators

  • Janssen Infectious Diseases BVBA Clinical Trial · Janssen Infectious Diseases BVBA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02262715 on ClinicalTrials.gov